Fate Therapeutics, Inc. (FATE)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
1.79 USD
-0.14
(-7.013%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 1.80 +0.01 (0.559%) ⇧ (Oct. 16, 2026, 6:30 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:50 a.m. EDT
The immediate outlook remains neutral despite a 'Buy' analyst consensus, as the company lacks the fundamental durability to support a high-conviction entry. While recent clinical data on FT836 has sparked a pop and insiders are buying, the balance sheet is fragile with massive negative free cash flow and no revenue, forcing reliance on capital markets. The lack of a dividend and negative earnings confirm this is a speculative vehicle, not an investment. The options market is pricing in a binary outcome where success leads to a massive re-rating, but failure leaves little room for error. Until the pipeline proves commercial viability and the cash runway extends significantly, the risk-reward profile favors waiting rather than committing capital. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044405 |
| AutoETS | 0.044632 |
| AutoARIMA | 0.058056 |
| MSTL | 0.066778 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.21 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.321 |
| Excess Kurtosis | -0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 49.32 |
| Revenue per Share | 0.054 |
| Market Cap | 214,478,704 |
| Forward P/E | -1.85 |
| Beta | 2.53 |
| Website | https://www.fatetherapeutics.com |
As of Oct. 10, 2026, 6:50 a.m. EDT: Speculators are positioning asymmetrically for upside, with heavy open interest in out-of-the-money calls (strikes 4.0 and 5.0) relative to puts, suggesting a bullish bias driven by clinical trial catalysts. However, significant put volume at the 3.0 strike in February 2027 indicates a specific hedge against downside risk if the next data readout underperforms.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.16233766 |
| Address1 | 12,278 Scripps Summit Drive |
| All Time High | 121.16 |
| All Time Low | 0.66 |
| Ask | 3.28 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.2 - Buy |
| Average Daily Volume10 Day | 1,340,780 |
| Average Daily Volume3 Month | 1,599,853 |
| Average Volume | 1,599,853 |
| Average Volume10Days | 1,340,780 |
| Beta | 2.528 |
| Bid | 1.91 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 1.315 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.79 |
| Current Ratio | 4.846 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.95 |
| Day Low | 1.78 |
| Debt To Equity | 49.32 |
| Display Name | Fate Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,715,288,400 |
| Earnings Call Timestamp Start | 1,715,288,400 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -120,502,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.132 |
| Enterprise To Revenue | 21.012 |
| Enterprise Value | 136,386,720 |
| Eps Current Year | -1.0175 |
| Eps Forward | -0.9675 |
| Eps Trailing Twelve Months | -1.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4024 |
| Fifty Day Average Change | -0.61240005 |
| Fifty Day Average Change Percent | -0.25491178 |
| Fifty Two Week Change Percent | 16.233767 |
| Fifty Two Week High | 3.23 |
| Fifty Two Week High Change | -1.44 |
| Fifty Two Week High Change Percent | -0.44582045 |
| Fifty Two Week Low | 0.95 |
| Fifty Two Week Low Change | 0.84 |
| Fifty Two Week Low Change Percent | 0.8842105 |
| Fifty Two Week Range | 0.95 - 3.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,380,634,200,000 |
| Float Shares | 105,752,387 |
| Forward Eps | -0.9675 |
| Forward P E | -1.8501292 |
| Free Cashflow | -48,659,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 161 |
| Fullday Change | -0.125 |
| Fullday Change Percent | -6.4935064 |
| Fullday Price | 1.79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -77,932,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.010650001 |
| Held Percent Institutions | 0.69966006 |
| Implied Shares Outstanding | 119,820,514 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California. |
| Long Name | Fate Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 214,478,704 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_39268712 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -125,996,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 291,762,951 |
| Number Of Analyst Opinions | 9 |
| Open | 1.94 |
| Operating Cashflow | -101,944,000 |
| Operating Margins | -14.953891 |
| Overall Risk | 7 |
| Phone | 858 875 1800 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.5586587 |
| Post Market Price | 1.8 |
| Post Market Time | 1,792,189,819 |
| Previous Close | 1.925 |
| Price Eps Current Year | -1.7592137 |
| Price Hint | 4 |
| Price To Book | 1.3612167 |
| Price To Sales Trailing12 Months | 33.042477 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.749 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.18182 |
| Region | US |
| Regular Market Change | -0.135 |
| Regular Market Change Percent | -7.01299 |
| Regular Market Day High | 1.95 |
| Regular Market Day Low | 1.78 |
| Regular Market Day Range | 1.78 - 1.95 |
| Regular Market Open | 1.94 |
| Regular Market Previous Close | 1.925 |
| Regular Market Price | 1.79 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 1,383,070 |
| Return On Assets | -0.26216 |
| Return On Equity | -0.6075 |
| Revenue Growth | 0.092 |
| Revenue Per Share | 0.054 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 119,820,514 |
| Shares Percent Shares Out | 0.08979999 |
| Shares Short | 10,759,313 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,111,011 |
| Short Name | Fate Therapeutics, Inc. |
| Short Percent Of Float | 0.1014 |
| Short Ratio | 7.34 |
| Source Interval | 15 |
| State | CA |
| Symbol | FATE |
| Target High Price | 8.0 |
| Target Low Price | 2.2 |
| Target Mean Price | 5.74444 |
| Target Median Price | 7.0 |
| Total Cash | 153,770,000 |
| Total Cash Per Share | 1.283 |
| Total Debt | 75,675,000 |
| Total Revenue | 6,491,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.90535 |
| Two Hundred Day Average Change | -0.11535001 |
| Two Hundred Day Average Change Percent | -0.060540065 |
| Type Disp | Equity |
| Volume | 1,383,070 |
| Website | https://www.fatetherapeutics.com |
| Zip | 92,131 |